Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer Strong safety profile for FRA-H with no loss of bodyweight as compared with control in animal models Success of tADC proof-of ...
Success of tADC proof-of-concept study paves way for creating multiple potential therapeutic candidates for preclinical and clinical evaluation NEW YORK, NY / ACCESSWIRE / September 11, 2024 / OS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results